DMARDS Flashcards
1
Q
Infliximab (Remicade)
A
- chimeric monoclonal antibody against tumor necrosis factor (TNF)-alpha
- combined with methotrexate
2
Q
MOA of Adalimumab (Humira)
A
-
human monoclonal antibody against TNF-alpha
- 100% human peptide sequences
3
Q
MOA Etanercept (Enbrel)
A
- fusion protein that is a decoy TNF-alpha receptor so TNF-alpha will bind to it and decrease pro-inflammatory effect
4
Q
MOA Abatacept (Orencia)
A
- fully human fusion protein that acts to Inhibit B-cell differentiation and T-cell activation
5
Q
Rituximab (Rituxan) MOA
A
- chimeric monoclonal antibody that binds to CD20 and Inhibits B-cell differentiation and T-cell activation
6
Q
Leflunomide (Arava)
A
- Inhibitor of dihydro-orotate dehydrogenase
- inhibits pyrimidine (nucleic acid)
- inhibits the induction of COX-2
7
Q
Micophenolate Mofetil (Cellcept)
A
- Inhibitors of nucleic acid synthesis
- inhibits lymphocyte purine synthesis
8
Q
MOA Anakinra (Kineret)
A
- Interleukin-1 receptor antagonist (IL-1Ra)
9
Q
Tofacitinib (Xeljanz)
A
- Janus kinase inhibitors (JAKs)
- JAK 1 and JAK 3
10
Q
source of TNF-alpha? primary effects?
A
- source: macrophages
- primary effects: prostaglandin production
- big player in chronic inflammation
11
Q
MOA of Aurothioglucose
A
- Inhibit phagocytosis
- Uncouple oxidative phosphorylation and inhibit cellular respiration
- React with proteins
- Suppress cellular immunity
- No analgesic effect
12
Q
toxicity of Aurothioglucose causes
A
- bone marrow damage
- enterocolitis
13
Q
Use of Penicillamine
A
- chelating drug
- rheumatoid arthritis
- wilson’s disease
14
Q
toxicites of Penicillamine
A
- incidence of adverse reactions high
- affects bone marrow
15
Q
use of Hydroxychloroquine (plaquenil)
A
- rheumatoid arthritis
- toxicity high
